- Home
- XCUR vs KALA Comparison
XCUR vs KALA Comparison
Compare XCUR & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XCUR
- KALA
- Stock Information
- Founded
- XCUR 2011
- KALA 2009
- Country
- XCUR United States
- KALA United States
- Employees
- XCUR N/A
- KALA N/A
- Industry
- XCUR Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- XCUR Health Care
- KALA Health Care
- Exchange
- XCUR Nasdaq
- KALA Nasdaq
- Market Cap
- XCUR 32.4M
- KALA 26.2M
- IPO Year
- XCUR N/A
- KALA 2017
- Fundamental
- Price
- XCUR $4.23
- KALA $1.67
- Analyst Decision
- XCUR
- KALA Buy
- Analyst Count
- XCUR 0
- KALA 3
- Target Price
- XCUR N/A
- KALA $31.50
- AVG Volume (30 Days)
- XCUR 30.7K
- KALA 2.7M
- Earning Date
- XCUR 11-13-2025
- KALA 11-11-2025
- Dividend Yield
- XCUR N/A
- KALA N/A
- EPS Growth
- XCUR N/A
- KALA N/A
- EPS
- XCUR N/A
- KALA N/A
- Revenue
- XCUR N/A
- KALA N/A
- Revenue This Year
- XCUR N/A
- KALA N/A
- Revenue Next Year
- XCUR N/A
- KALA N/A
- P/E Ratio
- XCUR N/A
- KALA N/A
- Revenue Growth
- XCUR N/A
- KALA N/A
- 52 Week Low
- XCUR $2.15
- KALA $1.10
- 52 Week High
- XCUR $36.00
- KALA $20.60
- Technical
- Relative Strength Index (RSI)
- XCUR 44.40
- KALA 27.87
- Support Level
- XCUR $4.12
- KALA $1.26
- Resistance Level
- XCUR $4.57
- KALA $1.69
- Average True Range (ATR)
- XCUR 0.34
- KALA 1.14
- MACD
- XCUR 0.15
- KALA -1.93
- Stochastic Oscillator
- XCUR 70.56
- KALA 2.80
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.